生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
Otsuka
and
Lundbeck
Announce
FDA
Acceptance of sNDA Filing for
Brexpiprazole
in Combination With
Sertraline
for the Treatment of Adults With
Post-Traumatic Stress Disorder (PTSD)
2024-06-25
·
交易
·
BioSpace
临床结果
临床3期
上市批准
申请上市
临床2期
The supplemental new drug application (sNDA) for
brexpiprazole
in combination with
sertraline
for the treatment of adults with
post-traumatic stress disorder (PTSD)
has been accepted and filed by the
FDA
. The
FDA
target date (PDUFA date) for completion of the review is February 8, 2025. If approved,
brexpiprazole
and
sertraline
combination treatment would be the first
FDA
-approved pharmacological option for
PTSD
in more than 20 years. PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--
Otsuka Pharmaceutical Co., Ltd.
(
Otsuka
) and
H. Lundbeck A/S
(
Lundbeck
) announce the
U.S. Food and Drug Administration (FDA)
has determined that the supplemental New Drug Application (sNDA) for
brexpiprazole
in combination with
sertraline
for the treatment of adults with
post-traumatic stress disorder (PTSD)
is sufficiently complete to permit a substantive review. The
FDA
has assigned the application for a Prescription Drug User Fee Act (PDUFA) target action date of February 8, 2025. This press release features multimedia. View the full release here: The sNDA submission is based on data from three randomized clinical trials evaluating the safety and efficacy of
brexpiprazole
in combination with
sertraline
in adult patients with
PTSD
. 1,2 The primary endpoint for all three trials was the change from randomization (Week 1) to Week 10 in the Clinician-Administered
PTSD
Scale (CAPS-5) total score for
brexpiprazole
and
sertraline
combination therapy versus
sertraline
plus placebo in patients diagnosed with
PTSD
according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).1 The trials were randomized, double blind, active-controlled, and Trial 061 (Phase II) and 071 (Phase III) were flexible dose trials, while Trial 072 (Phase III) was a fixed dose trial.1 In Trial 061 and 071,
brexpiprazole
in combination with
sertraline
was associated with a statistically significant reduction (p<0.05) in
PTSD
symptoms compared to
sertraline
plus placebo, as measured by the change in the CAPS-5 total score from randomization (Week 1) to Week 10 (primary endpoint). In Trial 072, while the primary endpoint was not met, reductions in
PTSD
symptoms with
brexpiprazole
in combination with
sertraline
were consistent with Trials 061 and 071. Improvements were consistently observed across the Clinical Global Impression Severity (CGI-S) scale and the four CAPS-5 clusters of re-experiencing, avoidance, negative cognition/mood and arousal/reactivity symptoms in Trials 061 and 071.1,3 Across the three randomized trials, the combination of
brexpiprazole
and
sertraline
in adult patients with
PTSD
was generally well-tolerated, and no new safety observations were identified. The safety and tolerability results were consistent with the known pro
brexpiprazole
in its approved indications and what has been observed in other clinical trials. The overall incidence of treatment-emergent adverse events (TEAEs) across the three trials was 55.5 percent with
brexpiprazole
plus
sertraline
, and 56.2 percent with
sertraline
plus placebo.2 “
Post-traumatic stress disorder
is one of the most common
mental health disorders
in the United States. Approximately 13 million adults in the
U.S.
have
PTSD
during a given year, and between seven to eight out of every 100 will experience
PTSD
at some point in their lives,”4-10 said John Kraus, M.D., Ph.D., executive vice president and chief medical officer,
Otsuka
. “This is a significant development, and we look forward to continuing our efforts to provide a treatment option that may benefit the millions of patients and caregivers who are impacted by the debilitating effects of
PTSD
.” “
Brexpiprazole
in combination with
sertraline
could represent an important advancement over current standard of care, and we look forward to working with the
FDA
in the process of seeking approval of this combination,” said Johan Luthman, Ph.D., executive vice president,
Lundbeck Research & Development
. “We are grateful to the patients and caregivers who participated in these important trials.” About CAPS-5 The Clinician-Administered
PTSD
Scale for DSM-5 (CAPS-5) is a structured interview designed to assess
PTSD
diagnostic status and symptoms severity as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). The interview consists of 30 items, with a higher score indicating a worse outcome. About
Post-Traumatic Stress Disorder
PTSD
is one of the most common
mental health disorders
in the United States, with approximately five percent of the population affected during a given year.6-10 It may occur in people who have experienced or witnessed a traumatic event, series of events or set of circumstances. An individual may experience this as emotionally or physically harmful or life-threatening and may affect mental, physical, social, and/or spiritual well-being. Examples include physical/sexual assault, natural disasters, serious accidents, terrorist acts, war/combat, historical trauma, intimate partner violence and bullying.11,12 Symptoms of
PTSD
are generally grouped into four clusters: intrusion (re-experiencing), avoidance, negative cognitions and mood, and marked alterations in arousal and reactivity.7,12 Symptoms can vary over time or vary from person to person.12 Symptoms usually begin within 3 months of the traumatic incident, but they sometimes emerge later. To meet the criteria for
PTSD
diagnosis, symptoms must last longer than one month, and they must be severe enough to interfere with aspects of daily life, such as relationships or work. Symptoms also must not be due to medications, substance use, or a medical condition.7 Guideline recommended first-line treatment includes psychotherapy (e.g., cognitive behavioral therapy) and first line pharmacotherapy options include certain antidepressants.13 About REXULTI (brexpiprazole)
Brexpiprazole
was approved in the
U.S.
in 2015, as an adjunctive therapy to antidepressants in adults with
major depressive disorder (MDD)
and as a treatment for
schizophrenia
in adults. Most recently,
brexpiprazole
was approved in the
U.S.
for the treatment of agitation associated with
dementia
due to
Alzheimer's disease
, in May 2023.
Brexpiprazole
was also approved by Health Canada for
schizophrenia
and adjunctive treatment of
MDD
in 2017 and 2019, respectively, and for agitation associated with
dementia
due to
Alzheimer's disease
in 2024. It was approved by the
European Medicines Agency
in 2018 for the treatment of
schizophrenia
and the Ministry of Health, Labour and Welfare in Japan for the treatment of
schizophrenia
and
MDD
in 2018 and 2023, respectively.14
Brexpiprazole
was discovered by
Otsuka
and is being co-developed by
Otsuka
and
Lundbeck
. The mechanism of action of
brexpiprazole
is unknown, however the efficacy of
brexpiprazole
may be mediated through a combination of partial agonist activity at
serotonin 5-HT1A
and
dopamine D2 receptors
, antagonist activity at
serotonin 5-HT2A receptors
, as well as antagonism of alpha 1B/2C receptors.14-16 About
Otsuka
Otsuka Pharmaceutical Co., Ltd.
is a global healthcare company with the corporate philosophy:
Otsuka
–people creating new products for better health worldwide.
Otsuka
researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals,
Otsuka
is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in
oncology
and on several under-addressed diseases including
tuberculosis
, a significant global public health issue. These commitments illustrate how
Otsuka
is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka
established a presence in the
U.S.
in 1973 and today its
U.S.
affiliates include
Otsuka Pharmaceutical Development & Commercialization, Inc.
(OPDC) and
Otsuka America Pharmaceutical, Inc.
(
OAPI
). These two companies’ 2,250 employees in the
U.S.
develop and commercialize medicines in the areas of mental health and nephrology, using cutting-edge technology to address unmet healthcare needs. OPDC and
OAPI
are indirect subsidiaries of
Otsuka Pharmaceutical Co., Ltd.
, which is a subsidiary of
Otsuka Holdings Co., Ltd.
headquartered in Tokyo, Japan. The
Otsuka group
of companies employed 34,400 people worldwide and had consolidated sales of approximately USD 14.2 billion in 2023. All
Otsuka
stories start by taking the road less traveled. Learn more about
Otsuka
in the
U.S.
at and connect with us on LinkedIn and Twitter at @OtsukaUS.
Otsuka Pharmaceutical Co., Ltd.
’s global website is accessible at About
Lundbeck
Lundbeck Pharmaceuticals LLC is a wholly owned US subsidiary of
H. Lundbeck A/S
(HLUNa / HLUNb, HLUNA DC / HLUNB DC), a global biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with
neurological and psychiatric diseases
. As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options. Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of. Too many people worldwide live with
brain diseases
– complex conditions often invisible to others that nonetheless take a tremendous toll on individuals, families and societies. We are committed to fighting stigma and discrimination against people living with
brain diseases
and advocating for broader social acceptance of people with brain health conditions. Every day, we strive for improved treatment and a better life for people living with
brain disease
. We have approximately 5,700 employees, and our products are available in more than 100 countries. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for
brain diseases
for which there are few, if any therapeutic options. We have research facilities in Denmark and the United States, and our production facilities are located in Denmark, France, and Italy.
Lundbeck US
comprises the wholly owned US subsidiaries of
H. Lundbeck A/S
(HLUNa / HLUNb, HLUNA DC / HLUNB DC) (“
Lundbeck
”), including
Lundbeck LLC
and Lundbeck Pharmaceuticals LLC. With a workforce of more than 1,000 colleagues,
Lundbeck US
is deeply committed to enhancing the lives of patients, families, and caregivers through focused innovation in neuroscience. For additional information, please visit Lundbeck.com/us and connect with us on LinkedIn and X at @LundbeckUS. INDICATIONS and IMPORTANT SAFETY INFORMATION for
REXULTI
® (
brexpiprazole
) INDICATIONS:
REXULTI
is a prescription medicine used: along with antidepressant medicines to treat
major depressive disorder (MDD)
in adults to treat
schizophrenia
in adults and children ages 13 years and older to treat
agitation
that may happen with
dementia
due to
Alzheimer’s disease
REXULTI
should not be used as an “as needed” treatment for
agitation
that may happen with
dementia
due to
Alzheimer’s disease
. It is not known if
REXULTI
is safe and effective in children with
MDD
. It is not known if
REXULTI
is safe and effective in children under 13 years of age with
schizophrenia
. IMPORTANT SAFETY INFORMATION: Increased risk of death in elderly people with
dementia-related psychosis
. Medicines like
REXULTI
can raise the risk of death in elderly people who have lost touch with reality (
psychosis
) due to
confusion
and
memory loss (dementia)
.
REXULTI
is not approved for the treatment of people with
dementia-related psychosis
without agitation that may happen with
dementia
due to
Alzheimer’s disease
. Increased risk of suicidal thoughts and actions.
REXULTI
and antidepressant medicines may increase suicidal thoughts and actions in pediatric patients and young adult patients, especially within the first few months of treatment or when the dose is changed.
Depression
and other
mental illnesses
are the most important causes of suicidal thoughts and actions. All patients on antidepressants and their families or caregivers should closely watch for new or worsening
depression
symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. Report any change in these symptoms immediately to the doctor. Do not take
REXULTI
if you are allergic to
brexpiprazole
or any of the ingredients in
REXULTI
.
REXULTI
may cause serious side effects, including: Cerebrovascular problems, including
stroke
, in elderly people with
dementia-related psychosis
that can lead to death.
Neuroleptic malignant syndrome (NMS)
is a serious condition that can lead to death. Call your healthcare provider or go to the nearest hospital emergency room right away if you have some or all of the following signs and symptoms of
NMS
:
high fever
; changes in your pulse, blood pressure, heart rate, and breathing; stiff muscles;
confusion
; increased sweating Uncontrolled body movements (
tardive dyskinesia
).
REXULTI
may cause movements that you cannot control in your face, tongue, or other body parts.
Tardive dyskinesia
may not go away, even if you stop taking
REXULTI
.
Tardive dyskinesia
may also start after you stop taking
REXULTI
. Problems with your metabolism such as: high blood sugar (
hyperglycemia
) and
diabetes
. Increases in blood sugar can happen in some people who take
REXULTI
. Extremely high blood sugar can lead to
coma
or death. Your healthcare provider should check your blood sugar before you start, or soon after you start
REXULTI
and then regularly during long term treatment with
REXULTI
. Call your healthcare provider if you have any of these symptoms of high blood sugar during treatment with
REXULTI
: feel very thirsty feel very hungry feel sick to your stomach need to urinate more than usual feel weak or tired feel confused, or your breath smells fruity increased fat levels (cholesterol and triglycerides) in your blood. Your healthcare provider should check the fat levels in your blood before you start, or soon after you start
REXULTI
, and then periodically during treatment with
REXULTI
. weight gain. You and your healthcare provider should check your weight before you start and often during treatment with
REXULTI
. Unusual and uncontrollable (compulsive) urges. Some people taking
REXULTI
have had strong unusual urges, to gamble and gambling that cannot be controlled (compulsive gambling). Other compulsive urges include sexual urges, shopping, and eating or binge eating. If you or your family members notice that you are having new or unusual strong urges or behaviors, talk to your healthcare provider. Low white blood cell count. Your healthcare provider may do blood tests during the first few months of treatment with
REXULTI
. Decreased blood pressure (
orthostatic hypotension
) and fainting. You may feel dizzy, lightheaded or pass out (faint) when you rise too quickly from a sitting or lying position. Falls. REXULTI may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (
orthostatic hypotension
), and can slow your thinking and motor skills which may lead to falls that can cause
fractures
or other injuries.
Seizures
(convulsions). Problems controlling your body temperature so that you feel too warm. Do not become too hot or dehydrated during treatment with
REXULTI
. Do not exercise too much. In hot weather, stay inside in a cool place if possible. Stay out of the sun. Do not wear too much clothing or heavy clothing. Drink plenty of water. Difficulty swallowing that can cause food or liquid to get into your lungs.
Sleepiness
, drowsiness, feeling tired, difficulty thinking and doing normal activities. Do not drive a car, operate machinery, or do other dangerous activities until you know how
REXULTI
affects you. REXULTI may make you feel drowsy. Before taking REXULTI, tell your healthcare provider about all of your medical conditions, including if you: have or have had heart problems or a
stroke
have or have had low or high blood pressure have or have had
diabetes
or high blood sugar or a family history of
diabetes
or high blood sugar. have or have had high levels of total cholesterol, LDL cholesterol, or triglycerides, or low levels of HDL cholesterol have or have had
seizures
(
convulsions
) have or have had kidney or liver problems have or have had a low white blood cell count are pregnant or plan to become pregnant.
REXULTI
may harm your unborn baby. Taking
REXULTI
during your third trimester of pregnancy may cause your baby to have abnormal muscle movements or withdrawal symptoms after birth. Talk to your healthcare provider about the risk to your unborn baby if you take
REXULTI
during pregnancy. Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with
REXULTI
. There is a pregnancy exposure registry for women who are exposed to
REXULTI
during pregnancy. If you become pregnant during treatment with
REXULTI
, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychiatric Medications. You can register by calling 1-866-961-2388 or visit . are breastfeeding or plan to breastfeed. It is not known if
REXULTI
passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with
REXULTI
. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
REXULTI
and other medicines may affect each other causing possible serious side effects.
REXULTI
may affect the way other medicines work, and other medicines may affect how
REXULTI
works. Your healthcare provider can tell you if it is safe to take
REXULTI
with your other medicines. Do not start or stop any medicines during treatment with
REXULTI
without first talking to your healthcare provider. The most common side effects of
REXULTI
include weight gain,
sleepiness
,
dizziness
,
common cold symptoms
, and
restlessness
or feeling like you need to move (akathisia). These are not all the possible side effects of
REXULTI
. For more information, ask your healthcare provider or pharmacist. You are encouraged to report side effects of
REXULTI
(
brexpiprazole
). Please contact
Otsuka America Pharmaceutical, Inc.
at 1-800-438-9927 or
FDA
at 1-800-FDA-1088 ( ). Please read FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE for
REXULTI
. References Behl S et al. Efficacy of
Brexpiprazole
in Combination with
Sertraline
for Patients with
Post-Traumatic Stress Disorder
: Summary of Data from Phase 2 and Phase 3 Randomized Clinical Trials. Presented at ASCP 2024 (May 28-31). Behl S et al. Safety and Tolerability of
Brexpiprazole
in Combination with
Sertraline
for Patients with
Post-Traumatic Stress Disorder
: Summary of Data from Phase 2 and Phase 3 Randomized Clinical Trials. Presented at ASCP 2024 (May 28-31). Behl, S. Clinical Program of
Brexpiprazole
in Combination with
Sertraline
for Patients with
Post-Traumatic Stress Disorder
. Panel presentation at ASCP May 28, 2024. Kilpatrick DG, Resnick HS, Milanak ME, Miller MW, Keyes KM, Friedman MJ. National estimates of exposure to traumatic events and
PTSD
prevalence using DSM-IV and DSM-5 criteria. J Trauma Stress. 2013;26(5):537-547. Koenen KC, Ratanatharathorn A, Ng L, et al.
Posttraumatic stress disorder
in the World Mental Health Surveys. Psychol Med. 2017;47(13):2260-2274. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H -U. Twelve-month and lifetime prevalence and lifetime morbid risk of
anxiety and mood disorders
in the United States. Int J Methods Psychiatr Res. 2012;21(3):169-184. Lancaster CL, Teeters JB, Gros DF, Back SE.
Posttraumatic Stress Disorder
: Overview of Evidence-Based Assessment and Treatment. J Clin Med. 2016;5(11):105. Lehavot K, Katon JG, Chen JA, Fortney JC, Simpson TL.
Post-traumatic Stress Disorder
by Gender and Veteran Status [published correction appears in Am J Prev Med. 2019 Oct;57(4):573]. Am J Prev Med. 2018;54(1):e1-e9. U.S. Department of Veterans Affairs. How Common Is
PTSD
in Adults? Last updated: Feb. 3, 2023. Last accessed: April 30, 2024. Available at: . US Census Bureau 2022 Data. American Psychiatric Association. What is
Posttraumatic Stress Disorder (PTSD)
? Last updated: November 2022. Last accessed: April 30, 2024. Available at: . American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013. VA/DoD Clinical Practice Guideline for Management of
PTSD
– Provider Summary 2023. Version 4.0. US Department of Veterans Affairs, US Department of Defense; 2023. Last accessed May 22, 2024. . Otsuka. Otsuka Pharmaceutical and Lundbeck Announce Topline Results from Two Phase 3 Trials of
Brexpiprazole
as Combination Therapy with
Sertraline
for the Treatment of
Post-Traumatic Stress Disorder
in Adults. Last accessed: May 20, 2024. Available at: . Maeda K, Sugino H, Akazawa H, et al.
Brexpiprazole
I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589-604.
REXULTI
® (
brexpiprazole
). Prescribing Information. FDA. Reference ID: 4911319. May 2023. © 2024 Otsuka America Pharmaceutical, Inc. All Rights Reserved. June 2024 11US24EBC0179
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Otsuka Pharmaceutical Co., Ltd.
H. Lundbeck A/S
US Food & Drug Administration
[+8]
适应症
创伤后应激障碍
行为障碍
重度抑郁症
[+26]
靶点
5-HT1A receptor
D2 receptor
5-HT2A receptor
药物
布瑞哌唑
盐酸舍曲林
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务